• iRhythm Technologies agreed to buy VitalConnect for about USD 287.5 million, expanding beyond ambulatory monitoring into inpatient and hospital-to-home settings.
• Consideration includes about USD 237.5 million in cash from iRhythm’s balance sheet, about USD 50 million in iRhythm common stock.
• VitalConnect adds mobile cardiac telemetry and continuous multi-vitals monitoring, broadening iRhythm’s cardiac monitoring platform.
• iRhythm expects the deal to lift its revenue growth rate starting in 2027 while maintaining its 15% adjusted EBITDA margin target for 2027.
• Closing is expected by the end of 2026; iRhythm will provide interim working capital financing starting with USD 10 million, up to USD 30 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061606PRIMZONEFULLFEED9805407) on August 06, 2026, and is solely responsible for the information contained therein.